【藥品性質提示】 #高警訊藥品 【藥品訊息】 Soliqua 黃 胰島素筆 衛教單張

糖尿病 (基礎胰島素) Diabetes mellitus, type 2

Lixisenatide: Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist
Lixisenatide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist. Acting on the same receptor as the endogenous hormone incretin, lixisenatide increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, and slows gastric emptying.
Insulin Glargine: Insulin, Long-Acting
Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.

Refer to individual agents.

Hypersensitivity to insulin glargine, lixisenatide, or any component of the formulation; during episodes of hypoglycemia

Adverse events were observed in some animal reproduction studies. Refer to individual monographs.

According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk and benefits. Refer to individual monographs.

Note: Also see individual agents.
Common:
1. Endocrine & metabolic: Hypoglycemia
2. Immunologic: Antibody development
Others:
1. Central nervous system: Headache
2. Endocrine & metabolic: Severe hypoglycemia
3. Gastrointestinal: Nausea, diarrhea, vomiting
4. Local: Injection site reaction
5. Respiratory: Nasopharyngitis, upper respiratory tract infection
6. Local: Hypertrophy or lipoatrophy at injection site
Postmarketing:
Abdominal distention, abdominal pain, constipation, decreased appetite, dyspepsia, flatulence, gastritis, gastroesophageal reflux disease

Patients naive to basal insulin or a GLP-1 agonist, or currently on a GLP-1 agonist or <30 units of basal insulin/day: 15 units (insulin glargine 15 units/lixisenatide 5 mcg) once daily
Patients currently on 30 to 60 units of basal insulin/day, with or without a GLP-1 agonist: 30 units (insulin glargine 30 units/lixisenatide 10 mcg) once daily
Dose titration: Titrate the dosage upwards or downwards by 2 to 4 units (insulin glargine 2 to 4 units/lixisenatide 0.66 to 1.32 mcg) every week until the desired fasting plasma glucose is achieved; usual dosage range: 15 units (insulin glargine 15 units/lixisenatide 5 mcg) to 60 units (insulin glargine 60 units/lixisenatide 20 mcg)/day. Maximum dose: 60 units (insulin glargine 60 units/lixisenatide 20 mcg)/day
Missed dose: If a dose is missed, resume with the next scheduled dose. Do not double dose or increase the dose to make up for the missed dose.

N/A

1. eGFR ≥15 mL/minute/1.73 m2 to <90 mL/minute/1.73 m2:
There are no specific dosage adjustments provided in the manufacturer's labeling for the combination product; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.
2. eGFR <15 mL/minute/1.73 m2:
Use is not recommended

There are no specific dosage adjustments provided in the manufacturer's labeling for the combination product; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.

1. Should be stored in the refrigerator (2 °C-8 °C).
2. Do not freeze or place it next to the freezer or ice pack.
3. The injection pen should be stored in the original outer box and should be kept in a dark place to avoid heat and light.